To include your compound in the COVID-19 Resource Center, submit it here.

Scholar goes to the clinic

Why Scholar Rock will use $47M series C to advance platform alongside SRK-015

While Scholar Rock LLC’s series C round will bring the biotech’s lead program into the clinic, investors also want continued investment in the company’s growth factor modulation platform to maximize its value.

On Jan. 3, Scholar Rock

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers